Cargando…

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways

Current therapeutic options for intrahepatic cholangiocarcinoma (ICC) are very limited, which is largely attributed to poor understanding of molecular pathogenesis of ICC. Breast cancer type 1 susceptibility protein-associated protein-1 (BAP1) has been reported to be a broad-spectrum tumor suppresso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xu-Xiao, Yin, Yue, Cheng, Jian-Wen, Huang, Ao, Hu, Bo, Zhang, Xin, Sun, Yun-Fan, Wang, Jian, Wang, Yu-Peng, Ji, Yuan, Qiu, Shuang-Jian, Fan, Jia, Zhou, Jian, Yang, Xin-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179995/ https://www.ncbi.nlm.nih.gov/pubmed/30305612 http://dx.doi.org/10.1038/s41419-018-1087-7

Ejemplares similares

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
por: Gao, Zheng, et al.
Publicado: (2022)

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
por: Andrici, Juliana, et al.
Publicado: (2016)

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
por: Marcus, Rebecca, et al.
Publicado: (2021)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways
por: Jiao, Chen Yu, et al.
Publicado: (2021)

Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma
por: Tang, Zheng, et al.
Publicado: (2019)

Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC
por: Wang, Zi, et al.
Publicado: (2015)

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
por: Sun, Bao-Ye, et al.
Publicado: (2023)

Evaluating prognostic value of biliary stone in intrahepatic cholangiocarcinoma by propensity score matching analysis
por: Wang, Yupeng, et al.
Publicado: (2023)

Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC
por: Wang, Zi, et al.
Publicado: (2019)

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma
por: Zhang, Chi, et al.
Publicado: (2013)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
por: Gao, Yang, et al.
Publicado: (2021)

Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma
por: Song, Fei, et al.
Publicado: (2021)

Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection
por: Jing, Chu-Yu, et al.
Publicado: (2016)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
por: Sun, Bao-Ye, et al.
Publicado: (2022)

JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma
por: Manieri, Elisa, et al.
Publicado: (2020)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling
por: Tang, Jing, et al.
Publicado: (2017)

Impact of cirrhosis on long‐term survival outcomes of patients with intrahepatic cholangiocarcinoma
por: Wang, Jian, et al.
Publicado: (2022)

Tumor suppressor BAP1 nuclear import is governed by transportin-1
por: Yang, Tzu-Jing, et al.
Publicado: (2022)

Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
por: Song, Fei, et al.
Publicado: (2020)

Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
por: Zhou, Zhengjun, et al.
Publicado: (2021)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target
por: Gao, Qiang, et al.
Publicado: (2014)

SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance
por: Chen, Jiafeng, et al.
Publicado: (2022)

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
por: Chai, Xiaoqiang, et al.
Publicado: (2022)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Overexpression of interleukin‐35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection
por: Zhang, Mei‐xia, et al.
Publicado: (2018)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro
por: Fan, Shanshan, et al.
Publicado: (2021)

Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection
por: Qu, Wei-Feng, et al.
Publicado: (2020)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Liu, Lingyun, et al.
Publicado: (2018)

Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma
por: Zhou, Shao-Lai, et al.
Publicado: (2021)

Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma
por: Sha, Meng, et al.
Publicado: (2019)

EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma
por: Hao, Xiao-Yi, et al.
Publicado: (2016)

Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma
por: Xin, Hao-Yang, et al.
Publicado: (2023)

Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
por: Zhang, Jun, et al.
Publicado: (2020)

BAP1: case report and insight into a novel tumor suppressor
por: Ghosh, Kanad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9tdiu2r1obe7e6vcthetm1e1g1